Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application.
.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 27(2024), 2 vom: 20. Feb., Seite 138-146 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Qi, Chang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 29.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3779/j.issn.1009-3419.2024.102.06 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36943188X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36943188X | ||
| 003 | DE-627 | ||
| 005 | 20240330001156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3779/j.issn.1009-3419.2024.102.06 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM36943188X | ||
| 035 | |a (NLM)38453446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Qi, Chang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application. | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Lung neoplasms | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Perioperative period | |
| 650 | 4 | |a Resectable non-small cell lung cancer | |
| 700 | 1 | |a Tian, Panwen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Weimin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo fei ai za zhi = Chinese journal of lung cancer |d 1998 |g 27(2024), 2 vom: 20. Feb., Seite 138-146 |w (DE-627)NLM199966222 |x 1999-6187 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:2 |g day:20 |g month:02 |g pages:138-146 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.06 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 2 |b 20 |c 02 |h 138-146 | ||